Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

Sanofi · найдено 123

Sanofi
Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
123 исследования
Завершено Фаза II Россия
SSR149415 · Sanofi

An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy, and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Patients With Major Depressive Disorder

324 участника во всех странах ClinicalTrials.gov DFI5879
Завершено Фаза III Россия
KETOPROFEN(RP19583); KETOPROFEN(RP19583); Placebo · Sanofi

A Randomised Double Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Doses of Ketoprofen Lysinate Lozenges (6.25 mg & 12.5 mg) in Patients With Sore Throat

801 участник во всех странах ClinicalTrials.gov KETOP_C_03968
Завершено Фаза III Россия
Lixisenatide (AVE0010); Lixisenatide Placebo; Sitagliptin; Sitagliptin Placebo; Metformin · Sanofi

A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin

319 участников во всех странах ClinicalTrials.gov EFC10780
Завершено Фаза III Россия
Insulin glulisine · Sanofi

Multicenter, Open, Non-randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine

Москва 1 центр 104 участника во всех странах ClinicalTrials.gov HMR1964A_3517
Прекращено Фаза III Россия
Dronedarone; Placebo (for Dronedarone) · Sanofi

A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors

3 236 участников во всех странах ClinicalTrials.gov EFC11405
Завершено Фаза III Россия
XRP6976 (Docetaxel/Taxotere) · Sanofi

A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

500 участников во всех странах ClinicalTrials.gov EFC6043
Завершено Фаза III Россия
Rimonabant (SR141716); Placebo · Sanofi

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin

Москва 1 центр 368 участников во всех странах ClinicalTrials.gov EFC5593
Завершено Фаза II Россия
ataciguat (HMR1766); placebo; cilostazol · Sanofi

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of HMR1766 Assessing the Efficacy and Safety of 3 Doses of HMR1766 Versus Placebo With Cilostazol as a Calibrator, Administered for 26 Weeks in Patients With Peripheral Arterial Disease (PAD) Fontaine Stage II

553 участника во всех странах ClinicalTrials.gov DFI6174
Завершено Фаза II–III Россия
Sarilumab; Placebo (for sarilumab); Methotrexate; Folic Acid · Sanofi

A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy

1 675 участников во всех странах ClinicalTrials.gov EFC11072
Завершено Фаза III Россия
Eliglustat GZ385660; Imiglucerase GZ437843 · Sanofi

Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3

57 участников во всех странах ClinicalTrials.gov EFC13738
Идёт Россия
OBS15333 · Sanofi

Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate to Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable

1 860 участников во всех странах ClinicalTrials.gov OBS15333
Завершено Фаза III Россия
insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA); placebo · Sanofi

A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Москва 1 центр 12 537 участников во всех странах ClinicalTrials.gov LTS6035
Завершено Фаза II Россия
SSR411298; Escitalopram; Placebo (for SSR411298) · Sanofi

An Eight-week, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Study, With Escitalopram (10 mg Daily) as Active Control, to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Doses of SSR411298 (10, 50, or 200 mg Daily) in Elderly Patients With Major Depressive Disorder

527 участников во всех странах ClinicalTrials.gov DFI10560
Завершено Фаза II Россия
LIXISENATIDE (AVE0010) · Sanofi

A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

542 участника во всех странах ClinicalTrials.gov DRI6012
Завершено Фаза III Россия
Semuloparin sodium; Enoxaparin sodium; Placebo · Sanofi

A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

2 326 участников во всех странах ClinicalTrials.gov EFC10342
Завершено Фаза III Россия
AVANAFIL; placebo · Sanofi

Clinical Trial on Efficacy and Tolerability of Two Different Single Doses of Avanafil in Russia

189 участников во всех странах ClinicalTrials.gov AVANAL07163
Завершено Фаза III Россия
Insulin glargine,300 U/mL; Insulin glargine (100 units /mL); Background therapy · Sanofi

6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period

463 участника во всех странах ClinicalTrials.gov EFC13957
Завершено Фаза III Россия
Lixisenatide (AVE0010); Placebo; Sulfonylurea; Metformin · Sanofi

A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea

859 участников во всех странах ClinicalTrials.gov EFC6015
Завершено Фаза III Россия
Lixisenatide (AVE0010); Exenatide; Metformin · Sanofi

A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin

639 участников во всех странах ClinicalTrials.gov EFC6019

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.